Hepatitis C virus NS5A replication complex inhibitors: The discovery of daclatasvir

Journal of Medicinal Chemistry

Volumn 57, Issue 5, 2014, Pages 2013-2032

  Belema, Makonen ^a   Nguyen, Van N ^a   Bachand, Carol ^a   Deon, Dan H ^a   Goodrich, Jason T ^a   James, Clint A ^c   Lavoie, Rico ^c   Lopez, Omar D ^a   Martel, Alain ^c   Romine, Jeffrey L ^a   Ruediger, Edward H ^c   Snyder, Lawrence B ^a   Laurent, Denis R St ^a   Yang, Fukang ^a   Zhu, Juliang ^a   Wong, Henry S ^a   Langley, David R ^b   Adams, Stephen P ^c   Cantor, Glenn H ^c   Chimalakonda, Anjaneya ^c   Fura, Aberra ^c   Johnson, Benjamin M ^c   Knipe, Jay O ^c   Parker, Dawn D ^c   Santone, Kenneth S ^c   Fridell, Robert A ^c   Lemm, Julie A ^c   O'Boyle, Donald R ^c   Colonno, Richard J ^c   Gao, Min ^c   Meanwell, Nicholas A ^a   Hamann, Lawrence G ^a   more..

^a Departments of Discovery Chemistry Synthesis   (United States)

^b Pharmaceutical Candidate Optimization   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASUNAPREVIR; DACLATASVIR; NONSTRUCTURAL PROTEIN 5A;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 1; MOUSE; NONHUMAN; RAT; REPLICON; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; ANTIVIRAL AGENTS; AREA UNDER CURVE; DOGS; DRUG DISCOVERY; ENZYME INHIBITORS; HEPACIVIRUS; IMIDAZOLES; MAGNETIC RESONANCE SPECTROSCOPY; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84896272204     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401836p     Document Type: Article

References (37)

1. Vaidya, A.; Perry, C. M. Simeprevir: First global approval Drugs 2013, 73, 2093-2106, and references cited therein
2. Lawitz, E.; Mangia, A.; Wyles, D.; Rodriguez-Torres, M.; Hassanein, T.; Gordon, S. C.; Schultz, M.; Davis, M. N.; Kayali, Z.; Reddy, K. R.; Jacobson, I. M.; Kowdley, K. V.; Nyberg, L.; Subramanian, G. M.; Hyland, R. H.; Arterburn, S.; Jiang, D.; McNally, J.; Brainard, D.; Symonds, W. T.; McHutchison, J. G.; Sheikh, A. M.; Younossi, Z.; Gane, E. J. Sofosbuvir for previously untreated chronic hepatitis C infection N. Engl. J. Med. 2013, 368, 1878-1887
3. TM (sofosbuvir) for the treatment of chronic hepatitis C. http://www.gilead.com/news/press-releases, Dec. 6, 2013.
4. Gao, M.; Nettles, R. E.; Belema, M.; Snyder, L. B.; Nguyen, V. N.; Fridell, R. A.; Serrano-Wu, M. H.; Langley, D. R.; Sun, J.-H.; O'Boyle, D. R., II; Lemm, J. A.; Wang, C.; Knipe, J. O.; Chien, C.; Colonno, R. J.; Grasela, D. M.; Meanwell, N. A.; Hamann, L. G. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 2010, 465, 96-100
5. Link, J. O.; Taylor, J. G.; Xu, L.; Mitchell, M. L.; Guo, H.; Liu, H.; Kato, D.; Kirschberg, T.; Sun, J.; Squires, N.; Parrish, J.; Kellar, T.; Yang, Z.-Y.; Yang, C.; Matles, M.; Wang, Y.; Wang, K.; Cheng, G.; Tian, Y.; Mogalian, E.; Mondou, E.; Cornpropst, M.; Perry, J.; Desai, M. C. The discovery of ledipasvir (GS-5885), a potent once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J. Med. Chem. DOI: 10.1021/jm401499.
6. Wilfret, D. A.; Walker, J.; Adkison, K. K.; Jones, L. A.; Lou, Y.; Gan, J.; Castellino, S.; Moseley, C. L.; Horton, J.; de Serres, M.; Culp, A.; Goljer, I.; Spreen, W. Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus NS5A, in healthy subjects and subjects chronically infected with genotype 1 hepatitis C virus Antimicrob. Agents Chemother. 2013, 57, 5037-5044
7. Coburn, C. A.; Meinke, P. T.; Chang, W.; Fandozzi, C. M.; Graham, D. J.; Hu, B.; Huang, Q.; Kargman, S.; Kozlowski, J.; Liu, R.; McCauley, J. A.; Nomeir, A. A.; Soll, R. M.; Vacca, J. P.; Wang, D.; Wu, H.; Zhong, B.; Olsen, D. B.; Ludmerer, S. W. Discovery of MK-8742: An HCV NS5A inhibitor with broad genotype activity ChemMedChem 2013, 8, 1930-1940
8. O'Boyle, D. R., II; Nower, P. T.; Lemm, J. A.; Valera, L.; Sun, J.-H.; Rigat, K.; Colonno, R.; Gao, M. Development of a cell-based high-throughput specificity screen using a hepatitis C virus-bovine viral diarrhea virus dual replicon assay Antimicrob. Agents Chemother. 2005, 49, 1346-1353
9. Lemm, J. A.; O'Boyle, D. R., II; Liu, M.; Nower, P. T.; Colonno, R.; Deshpande, M. S.; Snyder, L. B.; Martin, S. W.; St. Laurent, D. R.; Serrano-Wu, M. H.; Romine, J. L.; Meanwell, N. A.; Gao, M. Identification of hepatitis C virus NS5A inhibitors J. Virol. 2010, 84, 482-491
10. Lemm, J. A.; Leet, J. E.; O'Boyle, D. R., II; Romine, J. L.; Huang, X. S.; Schroeder, D. R.; Alberts, J.; Cantone, J. L.; Sun, J.-H.; Nower, P. T.; Martin, S. W.; Serrano-Wu, M. H.; Meanwell, N. A.; Snyder, L. B.; Gao, M. Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures Antimicrob. Agents Chemother. 2011, 55, 3795-3802
11. Najarro, P.; Mathews, N.; Cockerill, S. NS5A inhibitors. Hepatitis C Viruses, Tan, S. -L., Ed.; Horizon Bioscience: Wymondham, U.K, 2006; pp 271-292.
12. Conte, I.; Giuliano, C.; Ercolani, C.; Narjes, F.; Koch, U.; Rowley, M.; Altamura, S.; De Francesco, R.; Neddermann, P.; Migliaccio, G.; Stansfield, I. Synthesis and SAR of piperazinyl- N -phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture Bioorg. Med. Chem. Lett. 2009, 19, 1779-1783
13. Krueger, A. C.; Madigan, D. L.; Beno, D. W.; Betebenner, D. A.; Carrick, R.; Green, B. E.; He, W.; Liu, D.; Maring, C. J.; McDaniel, K. F.; Mo, H.; Molla, A.; Motter, C. E.; Pilot-Matias, T. J.; Tufano, M. D.; Kempf, D. J. Novel hepatitis C virus replicon inhibitors: synthesis and structure-activity relationships of fused pyrimidine derivatives Bioorg. Med. Chem. Lett. 2012, 22, 2212-2215
14. DeGoey, D. A.; Betebenner, D. A; Grampovnik, D. J.; Liu, D.; Pratt, J. K.; Tufano, M. D.; He, W.; Krishnan, P.; Pilot-Matias, T. J.; Marsh, K. C.; Molla, A.; Kempf, D. J.; Maring, C. J. Discovery of pyrido[2,3- d ]pyrimidine-based inhibitors of HCV NS5A Bioorg. Med. Chem. Lett. 2013, 23, 3627-3630
15. Romine, J. L.; St. Laurent, D. R.; Leet, J. E.; Martin, S. W.; Serrano-Wu, M. H.; Yang, F.; Gao, M.; O'Boyle, D. R., II; Lemm, J. A.; Sun, J.-H.; Nower, P. T.; Huang, X.; Deshpande, M. S.; Meanwell, N. A.; Snyder, L. B. Inhibitors of HCV NS5A: From iminothiazolidinones to symmetrical stilbenes ACS Med. Chem. Lett 2011, 2, 224-229
16. St. Laurent, D. R.; Belema, M.; Gao, M.; Goodrich, J.; Kakarla, R.; Knipe, J. O.; Lemm, J. A.; Liu, M.; Lopez, O. D.; Nguyen, V. N.; Nower, P. T.; O'Boyle, D., II; Qiu, Y.; Romine, J. L.; Serrano-Wu, M. H.; Sun, J.-H.; Valera, L.; Yang, F.; Yang, X.; Meanwell, N. A.; Snyder, L. B. HCV NS5A replication complex inhibitors. Part 2: Investigation of stilbene prolinamides Bioorg. Med. Chem. Lett. 2012, 22, 6063-6066
17. Lopez, O. D.; Nguyen, V. N.; St. Laurent, D. R.; Belema, M.; Serrano-Wu, M. H.; Goodrich, J. T.; Yang, F.; Qiu, Y.; Ripka, A. S.; Nower, P. T.; Valera, L.; Liu, M.; O'Boyle, D. R., II; Sun, J.-H.; Fridell, R. A.; Lemm, J. A.; Gao, M.; Good, A. C.; Meanwell, N. A.; Snyder, L. B. HCV NS5A replication complex inhibitors. Part 3: Discovery of potent analogues with distinct core topologies Bioorg. Med. Chem. Lett. 2013, 23, 779-784
18. St. Laurent, D. R.; Serrano-Wu, M. H.; Belema, M.; Ding, M.; Fang, H.; Gao, M.; Goodrich, J. T.; Krause, R. G.; Lemm, J. A.; Liu, M.; Lopez, O.; Nguyen, V. N.; Nower, P. T.; O'Boyle, D. R., II; Pearce, B. C.; Romine, J. L.; Valera, L.; Sun, J.-H.; Wang, Y.-K.; Yang, F.; Yang, X.; Meanwell, N. A.; Snyder, L. B. HCV NS5A replication complex inhibitors. Part 4: Optimization for genotype 1a replicon inhibitory activity. J. Med. Chem. DOI: 10.1021/jm301796k.
19. Belema, M.; Nguyen, V. N.; St. Laurent, D. R.; Lopez, O. D.; Qiu, Y.; Good, A. C.; Nower, P. T.; Valera, L.; O'Boyle, D. R., II; Sun, J.-H.; Liu, M.; Fridell, R. A.; Lemm, J. A.; Gao, M.; Knipe, J. O.; Meanwell, N. A.; Snyder, L. B. HCV NS5A replication complex inhibitors. Part 5: Discovery of potent and pan-genotypic glycinamide cap derivatives Bioorg. Med. Chem. Lett. 2013, 23, 4428-4435
20. Belema, M.; Nguyen, V. N.; Romine, J. L.; St. Laurent, D. R.; Lopez, O. D.; Goodrich, J.; Nower, P. T.; O'Boyle, D. R., II; Lemm, J. A.; Fridell, R. A.; Gao, M.; Fang, H.; Krause, R. G.; Wang, Y.-K.; Oliver, A. J.; Good, A. C.; Knipe, J. O.; Meanwell, N. A.; Snyder, L. B. Hepatitis C virus NS5A replication complex inhibitors. Part 6: The discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons. J. Med. Chem. DOI: 10.1021/jm4016203.
21. Lovering, F.; Bikker, J.; Humblet, C. Escape from flatland: Increasing saturation as an approach to improving clinical success J. Med. Chem. 2009, 52, 6752-6756
22. Ritchie, T. J.; Macdonald, S. J. F. The impact of aromatic ring count on compound developability-are too many aromatic rings a liability in drug design? Drug Discovery Today 2009, 14, 1011-1020
23. Wang, C.; Valera, L.; Jia, L.; Kirk, M. J.; Gao, M.; Fridell, R. A. In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A Antimicrob. Agents Chemother. 2013, 57, 611-613
24. Nettles, R. E.; Gao, M.; Bifano, M.; Chung, E.; Persson, A.; Marbury, T. C.; Goldwater, R.; DeMicco, M. P.; Rodriguez-Torres, M.; Vutikullird, A.; Fuentes, E.; Lawitz, E.; Lopez-Talavera, J. C.; Grasela, D. M. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitic C virus genotype 1 Hepatology 2011, 54, 1956-1965
25. Lok, A. S.; Gardiner, D. F.; Lawitz, E.; Martorell, C.; Everson, G. T.; Ghalib, R.; Reindollar, R.; Rustgi, V.; McPhee, F.; Wind-Rotolo, M.; Persson, A.; Zhu, K.; Dimitrova, D. I.; Eley, T.; Guo, T.; Grasela, D. M.; Pasquinelli, C. Preliminary study of two antiviral agents for hepatitis C genotype 1 N. Engl. J. Med. 2012, 366, 216-224
26. Chayanna, K.; Takahashi, S.; Toyota, J.; Karino, Y.; Ikeda, K.; Ishikawa, H.; Watanabe, H.; McPhee, F.; Hughes, E.; Kumada, H. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders Hepatology 2012, 55, 742-748
27. Suzuki, Y.; Ikeda, K.; Suzuki, F.; Toyota, J.; Karino, Y.; Chayama, K.; Kawakami, Y.; Ishikawa, H.; Watanabe, H.; Hu, W.; Eley, T.; McPhee, F.; Hughes, E.; Kumada, H. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options J. Hepatology 2013, 58, 655-662
28. Pol, S.; Ghalib, R. H.; Rustgi, V. K.; Matorell, C.; Everson, G. T.; Tatum, H. A.; Hezode, C.; Lim, J. K.; Bronowicki, J. P.; Abrams, G. A.; Brau, N.; Morris, D. W.; Thuluvath, P. J.; Reindollar, R. W.; Yin, P. D.; Diva, U.; Hindes, R.; McPhee, F.; Hernandez, D.; Wind-Rotolo, M.; Hughes, E. A.; Schnittman, S. Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomized, parallel-group, double-blind, placebo-controlled, dose-finding phase 2a trial Lancet 2012, 12, 671-677
29. Herbst, D. A.; Reddy, K. R. NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection Expert Opin. Invest. Drugs 2013, 22, 1337-1346
30. Everson, G. T.; Sims, K. D.; Rodriguez-Torres, M.; Hezode, C.; Lawitz, E.; Bourliere, M.; Loustaud-Ratti, V.; Rustgi, V.; Schwartz, H.; Tatum, H.; Marcellin, P.; Pol, S.; Thuluvath, P. J.; Eley, T.; Wang, X.; Huang, S.-P.; McPhee, F.; Wind-Rotolo, M.; Chung, E.; Pasquinelli, C.; Grasela, D. M.; Gardiner, D. F. Efficacy of an interferon- and Ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naÏve patients with HCV genotype 1 infection. Gastroenterology 2014, 146, 420-429.
31. Targett-Adams, P.; Graham, E. J. S.; Middleton, J.; Palmer, A.; Shaw, S. M.; Lavender, H.; Brain, P.; Tran, T. D.; Jones, L. H.; Wakenhut, F.; Stammen, B.; Pryde, D.; Pickford, C.; Westby, M. Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: Insights into compound modes of action J. Virol. 2011, 85, 6353-6368
32. Lee, C.; Ma, H.; Hang, J. Q.; Leveque, V.; Sklan, E. H.; Elazar, M.; Klumpp, K.; Glenn, J. S. The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein Virology 2011, 414, 10-18
33. Guedj, J.; Dahari, H.; Rong, L.; Sansone, N. D.; Nettles, R. E.; Cotler, S. J.; Layden, T. J.; Uprichard, S. L.; Perelson, A. S. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 3991-3996
34. Bachand, C.; Belema, M.; Deon, D. H.; Good, A. C.; Goodrich, J. T.; James, C. A.; Lavoie, R.; Lopez, O. D.; Martel, A.; Meanwell, N. A.; Nguyen, V. N.; Romine, J. L.; Ruediger, E. H.; Snyder, L. B.; St. Laurent, D. R.; Yang, F.; Langley, D. R.; Wang, G.; Hamann, L. G. Hepatitis C Virus Inhibitors. PCT Intl. Application. 2008, Patent No. WO2008-021927.
35. Poitout, L.; Roubert, P.; Contour-Galcera, M.-O.; Moinet, C.; Lannoy, J.; Pommier, J.; Plas, P.; Bigg, D.; Thurieau, C. Identification of potent non-peptide somatostatin antagonists with sst3 selectivity J. Med. Chem. 2001, 44, 2990-3000
36. Wang, X.; Rabbat, P.; O'Shea, P.; Tillyer, R.; Grabowski, E. J. J.; Reider, P. J. Selective monolithiation of 2,5-dibromopyridine with butyllithium Tetrahedon Lett 2000, 41, 4335-4338
37. Shah, N.; Pierce, T.; Kowdley, K. V. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C Expert Opin. Invest. Drugs 2013, 22, 1107-1121